ERBB2 and breast cancer: The results showed that HER2 status was significantly inconsistent between the primary breast cancer and metastases,37% exhibited heterogeneous HER2 expression between primary breast tumors and metastases, most of which changed from HER2 low expression to HER2–0 expression (34).Federica Miglietta et al.